PMID- 14623077 OWN - NLM STAT- MEDLINE DCOM- 20031218 LR - 20190621 IS - 0014-5793 (Print) IS - 0014-5793 (Linking) VI - 554 IP - 3 DP - 2003 Nov 20 TI - Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. PG - 264-70 AB - When oxygen becomes limiting, cells shift primarily to a glycolytic mode for generation of energy. A key regulator of glycolytic flux is fructose-2,6-bisphosphate (F-2,6-BP), a potent allosteric regulator of 6-phosphofructo-1-kinase (PFK-1). The levels of F-2,6-BP are maintained by a family of bifunctional enzymes, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB or PFK-2), which have both kinase and phosphatase activities. Each member of the enzyme family is characterized by their phosphatase:kinase activity ratio (K:B) and their tissue-specific expression. Previous work demonstrated that one of the PFK-2 isozyme genes, PFKFB-3, was induced by hypoxia through the hypoxia-inducible factor-1 (HIF-1) pathway. In this study we examined the basal and hypoxic expression of three members of this family in different organs of mice. Our findings indicate that all four isozymes (PFKFB-1-4) are responsive to hypoxia in vivo. However, their basal level of expression and hypoxia responsiveness varies in the different organs studied. Particularly, PFKFB-1 is highly expressed in liver, heart and skeletal muscle, with the highest response to hypoxia found in the testis. PFKFB-2 is mainly expressed in the lungs, brain and heart. However, the highest hypoxia responses are found only in liver and testis. PFKFB-3 has a variable low basal level of expression in all organs, except skeletal muscle, where it is highly expressed. Most importantly, its hypoxia responsiveness is the most ample of all three genes, being strongly induced in the lungs, liver, kidney, brain, heart and testis. Further studies showed that PFKFB-1 and PFKFB-2 were highly responsive to hypoxia mimics such as transition metals, iron chelators and inhibitors of HIF hydroxylases, suggesting that the hypoxia responsiveness of these genes is also regulated by HIF proteins. In summary, our data demonstrate that PFK-2 genes are responsive to hypoxia in vivo, indicating a physiological role in the adaptation of the organism to environmental or localized hypoxia/ischemia. FAU - Minchenko, Oleksandr AU - Minchenko O AD - Department of Molecular Biology, Institute of Biochemistry, National Academy of Science of Ukraine, Kiev 01601, Ukraine. FAU - Opentanova, Iryna AU - Opentanova I FAU - Caro, Jaime AU - Caro J LA - eng GR - R01 CA089212/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. PL - England TA - FEBS Lett JT - FEBS letters JID - 0155157 RN - 0 (DNA-Binding Proteins) RN - 0 (Enzyme Inhibitors) RN - 0 (HIF1A protein, human) RN - 0 (Hif1a protein, mouse) RN - 0 (Hif1a protein, rat) RN - 0 (Hypoxia-Inducible Factor 1) RN - 0 (Hypoxia-Inducible Factor 1, alpha Subunit) RN - 0 (Isoenzymes) RN - 0 (Nuclear Proteins) RN - 0 (Proteins) RN - 0 (RNA, Messenger) RN - 0 (Transcription Factors) RN - 3G0H8C9362 (Cobalt) RN - EC 2.7.1.105 (PFKFB3 protein, human) RN - EC 2.7.1.105 (Phosphofructokinase-2) RN - J06Y7MXW4D (Deferoxamine) RN - TE7660XO1C (Glycine) SB - IM MH - Animals MH - Cell Hypoxia/physiology MH - Cell Line, Tumor MH - Cobalt/pharmacology MH - DNA-Binding Proteins/metabolism MH - Deferoxamine/pharmacology MH - Enzyme Induction/drug effects MH - Enzyme Inhibitors/pharmacology MH - Gene Expression Regulation, Enzymologic/drug effects/*physiology MH - Glycine/analogs & derivatives/pharmacology MH - HeLa Cells MH - Humans MH - Hypoxia-Inducible Factor 1 MH - Hypoxia-Inducible Factor 1, alpha Subunit MH - Isoenzymes/biosynthesis/genetics MH - Mice MH - Mice, Inbred C57BL MH - Nuclear Proteins/metabolism MH - Organ Specificity MH - Phosphofructokinase-2 MH - *Protein Biosynthesis MH - Proteins/genetics MH - RNA, Messenger/biosynthesis MH - Rats MH - *Transcription Factors EDAT- 2003/11/19 05:00 MHDA- 2003/12/19 05:00 CRDT- 2003/11/19 05:00 PHST- 2003/11/19 05:00 [pubmed] PHST- 2003/12/19 05:00 [medline] PHST- 2003/11/19 05:00 [entrez] AID - S0014579303011797 [pii] AID - 10.1016/s0014-5793(03)01179-7 [doi] PST - ppublish SO - FEBS Lett. 2003 Nov 20;554(3):264-70. doi: 10.1016/s0014-5793(03)01179-7.